Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Holdings Reduced by Continental Advisors LLC

Continental Advisors LLC lessened its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 5.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 341,118 shares of the company's stock after selling 20,500 shares during the period. Teva Pharmaceutical Industries accounts for approximately 3.5% of Continental Advisors LLC's holdings, making the stock its 6th biggest position. Continental Advisors LLC's holdings in Teva Pharmaceutical Industries were worth $7,518,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Diversify Advisory Services LLC boosted its stake in Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after purchasing an additional 496 shares during the period. Sanctuary Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after purchasing an additional 664 shares during the period. Thrivent Financial for Lutherans boosted its stake in Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after purchasing an additional 699 shares during the period. Townsquare Capital LLC boosted its stake in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after purchasing an additional 812 shares during the period. Finally, Metis Global Partners LLC boosted its stake in Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after purchasing an additional 860 shares during the period. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Up 1.1 %

NYSE:TEVA traded up $0.16 during trading hours on Friday, hitting $14.88. 6,566,648 shares of the company's stock traded hands, compared to its average volume of 9,929,030. The firm has a market cap of $16.87 billion, a P/E ratio of -10.26, a P/E/G ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock's fifty day moving average price is $15.23 and its two-hundred day moving average price is $17.56.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on TEVA. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Bank of America reduced their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday. Finally, Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.